Zobrazeno 1 - 10
of 255
pro vyhledávání: '"Naureen Starling"'
Autor:
Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThis study aimed to identify microRNAs (miRs) as circulating biomarkers of resistance to first-line trastuzumab-based therapy in advanced HER2-positive oesophago-gastric cancer patients.MethodsA high-throughput 1015 Exiqon miRCURY LNA™ mi
Externí odkaz:
https://doaj.org/article/ce00e101c55741ff998c109728418068
Autor:
David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended.
Externí odkaz:
https://doaj.org/article/8c4c528d564e402aa51ff80d19849ea5
Autor:
Susanna Slater, Annette Bryant, Hsiang-Chi Chen, Ruwaida Begum, Isma Rana, Maria Aresu, Clare Peckitt, Oleg Zhitkov, Retchel Lazaro-Alcausi, Victoria Borja, Rachel Powell, David Lowery, Michael Hubank, Thereasa Rich, Gayathri Anandappa, Ian Chau, Naureen Starling, David Cunningham
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies patients to gu
Externí odkaz:
https://doaj.org/article/fd82327f73c3444fa40eeb618feddeee
Autor:
Fiona Turkes, Annette Bryant, Ruwaida Begum, Michael Davidson, Eleftheria Kalaitzaki, Maria Aresu, Retchel Lazaro-Alcausi, Jane Bryant, Isma Rana, Sue Chua, Lauren Aronson, Sanna Hulkki-Wilson, Charlotte Fribbens, David Watkins, Sheela Rao, Naureen Starling, David Cunningham, Irene Y. Chong, Ian Chau
Publikováno v:
Current Oncology, Vol 29, Iss 4, Pp 2174-2184 (2022)
Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of
Externí odkaz:
https://doaj.org/article/5d5338a80b2f46c49f2a37fe4ad17d3e
Autor:
Steve Harris, Jim Davies, Ben Glampson, Kerrie Woods, Niels Peek, Khurum Khan, Naureen Starling, Rachel Turner, Helen JS Jones, Chris Cunningham, Dimitri Papadimitriou, Lee Malcomson, Rachel Carten, Erik Mayer, Luca Mercuri, Eva JA Morris, Harpreet Wasan, Andrew Renehan, William Perry, Andres Tamm, Des Campbell, Algirdas Galdikas, Louise English, Alex Garbett, Stephanie Little, Sheila Matharu, Rebecca Muirhead, Ruth Norris, Catherine O’Hara, Gail Roadknight, Marion Teare, Kinga A Várnai
Publikováno v:
BMJ Health & Care Informatics, Vol 29, Iss 1 (2022)
Objective Colorectal cancer is a common cause of death and morbidity. A significant amount of data are routinely collected during patient treatment, but they are not generally available for research. The National Institute for Health Research Health
Externí odkaz:
https://doaj.org/article/a169a66932e746c5bfa2593393c62b43
Autor:
Pietro Carotenuto, Francesco Amato, Andrea Lampis, Colin Rae, Somaieh Hedayat, Maria C. Previdi, Domenico Zito, Maya Raj, Vincenza Guzzardo, Francesco Sclafani, Andrea Lanese, Claudia Parisi, Caterina Vicentini, Ian Said-Huntingford, Jens C. Hahne, Albert Hallsworth, Vladimir Kirkin, Kate Young, Ruwaida Begum, Andrew Wotherspoon, Kyriakos Kouvelakis, Sergio Xavier Azevedo, Vasiliki Michalarea, Rosie Upstill-Goddard, Sheela Rao, David Watkins, Naureen Starling, Anguraj Sadanandam, David K. Chang, Andrew V. Biankin, Nigel B. Jamieson, Aldo Scarpa, David Cunningham, Ian Chau, Paul Workman, Matteo Fassan, Nicola Valeri, Chiara Braconi
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Understanding which patients will respond to FOLFIRINOX therapy is important for clinical outcome. Here, the authors show that the MIR1307 is increased pancreatic cancer cell lines and inhibition of the microRNA sensitises cells to treatment.’ stra
Externí odkaz:
https://doaj.org/article/a029501cd4ea4989bf6d137ae286835e
Publikováno v:
Cancers, Vol 15, Iss 12, p 3248 (2023)
Gastric cancer is an aggressive disease with survival remaining poor in the advanced setting. More than a decade after the first targeted treatment was approved, still only HER2, MSI and PDL-1 status have reached everyday practice in terms of guiding
Externí odkaz:
https://doaj.org/article/e4847c0212a0495b8426139f74a2d74d
Autor:
Alice Newey, Beatrice Griffiths, Justine Michaux, Hui Song Pak, Brian J. Stevenson, Andrew Woolston, Maria Semiannikova, Georgia Spain, Louise J. Barber, Nik Matthews, Sheela Rao, David Watkins, Ian Chau, George Coukos, Julien Racle, David Gfeller, Naureen Starling, David Cunningham, Michal Bassani-Sternberg, Marco Gerlinger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics to investigate neo
Externí odkaz:
https://doaj.org/article/32b7ab7a83d34330933a0f79b7abfe76
Publikováno v:
Cancers, Vol 14, Iss 20, p 5105 (2022)
Circulating tumour DNA (ctDNA) has potential applications in gastric cancer (GC) with respect to screening, the detection of minimal residual disease (MRD) following curative surgery, and in the advanced disease setting for treatment decision making
Externí odkaz:
https://doaj.org/article/cef88dce094448d4b067271d0e281550
Autor:
Reyes Gonzalez-Exposito, Maria Semiannikova, Beatrice Griffiths, Khurum Khan, Louise J. Barber, Andrew Woolston, Georgia Spain, Katharina von Loga, Ben Challoner, Radhika Patel, Michael Ranes, Amanda Swain, Janet Thomas, Annette Bryant, Claire Saffery, Nicos Fotiadis, Sebastian Guettler, David Mansfield, Alan Melcher, Thomas Powles, Sheela Rao, David Watkins, Ian Chau, Nik Matthews, Fredrik Wallberg, Naureen Starling, David Cunningham, Marco Gerlinger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cel
Externí odkaz:
https://doaj.org/article/ed3d536126fe414a9681258db65b3503